A Prognostic Model for Brain Glioma Patients Based on 9 Signature Glycolytic Genes

Objective. To screen glycolytic genes linked to the glioma prognosis and construct the prognostic model. Methods. The relevant data of glioma were downloaded from TCGA and GTEx databases. GSEA of glycolysis-related pathways was carried out, and enriched differential genes were extracted. Screening out prognostic-related genes with conspicuous significance and construction of the prognostic model were conducted by multivariate Cox regression analysis and Lasso regression analysis. The model was evaluated, and cBioPortal was used to analyze the mutation of the model gene. The expression of the model gene in tumor and normal colon tissue was analyzed. The model was used to evaluate the prognosis of patients in different groups to verify the applicability of the model. Results. 339 differentially glycolytic-related genes were enriched in REACTOME_GLYCOLYSIS, GLYCOLYTIC_PROCESS, HALLMARK_GLYCOLYSIS, and other pathways. We obtained 9 key prognostic genes and constructed the prognostic evaluation model. The 3-year AUC values of the ROC curve display model are greater than 0.75, which indicates that the accuracy of the model is good. The relation of age and risk score to prognosis is shown by univariate and multivariate Cox analysis. The expression of SRD5A3, MDH2, and B3GAT3 genes was significantly upregulated in the tumor tissues, while the HDAC4 and G6PC2 genes were downregulated. The mutation rate of MDH2 and HDAC4 genes was the highest. This model could effectively distinguish the risk of poor prognosis of patients in any age stage. Conclusion. The prognostic assessment models based on glycolysis-related nine-gene signature could accurately predict the prognosis of patients with GBM.

Download Full-text

Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma

Technology in Cancer Research & Treatment ◽

10.1177/15330338211041425 ◽

2021 ◽

Vol 20 ◽

pp. 153303382110414

Author(s):

Xiaoyong Li ◽

Jiaqong Lin ◽

Yuguo pan ◽

Peng Cui ◽

Jintang Xia

Keyword(s):

Hepatocellular Carcinoma ◽

Overall Survival ◽

Regression Analysis ◽

Prognostic Model ◽

Cox Regression ◽

Risk Group ◽

Gene Signature ◽

Regression Analyses ◽

Related Gene ◽

Cox Regression Analysis

Background: Liver progenitor cells (LPCs) play significant roles in the development and progression of hepatocellular carcinoma (HCC). However, no studies on the value of LPC-related genes for evaluating HCC prognosis exist. We developed a gene signature of LPC-related genes for prognostication in HCC. Methods: To identify LPC-related genes, we analyzed mRNA expression arrays from a dataset (GSE57812 & GSE 37071) containing LPCs, mature hepatocytes, and embryonic stem cell samples. HCC RNA-Seq data from The Cancer Genome Atlas (TCGA) were used to explore the differentially expressed genes (DEGs) related to prognosis through DEG analysis and univariate Cox regression analysis. Lasso and multivariate Cox regression analyses were performed to construct the LPC-related gene prognostic model in the TCGA training dataset. This model was validated in the TCGA testing set and an external dataset (International Cancer Genome Consortium [ICGC] dataset). Finally, we investigated the relationship between this prognostic model with tumor-node-metastasis stage, tumor grade, and vascular invasion of HCC. Results: Overall, 1770 genes were identified as LPC-related genes, of which 92 genes were identified as DEGs in HCC tissues compared with normal tissues. Furthermore, we randomly assigned patients from the TCGA dataset to the training and testing cohorts. Twenty-six DEGs correlated with overall survival (OS) in the univariate Cox regression analysis. Lasso and multivariate Cox regression analyses were performed in the TCGA training set, and a 3-gene signature was constructed to stratify patients into 2 risk groups: high-risk and low-risk. Patients in the high-risk group had significantly lower OS than those in the low-risk group. Receiver operating characteristic curve analysis confirmed the signature's predictive capacity. Moreover, the risk score was confirmed to be an independent predictor for patients with HCC. Conclusion: We demonstrated that the LPC-related gene signature can be used for prognostication in HCC. Thus, targeting LPCs may serve as a therapeutic alternative for HCC.

Download Full-text

Identification of Prognostic Gene Signature Associated with Tumor Microenvironment of Cholangiocarcinoma

10.21203/rs.3.rs-524410/v1 ◽

2021 ◽

Author(s):

Jixiang Cao ◽

Xi Chen ◽

Guang Lu ◽

Haowei Wang ◽

Xinyu Zhang ◽

...

Keyword(s):

Regression Analysis ◽

Tumor Microenvironment ◽

Immune Cells ◽

Prognostic Model ◽

Cox Regression ◽

Gene Signature ◽

Risk Scores ◽

Tumor Infiltration ◽

Prognostic Signature ◽

Cox Regression Analysis

Abstract Background: Cholangiocarcinoma (CCA) is the most common malignancy of the biliary tract with a dismal prognosis. Increasing evidence suggests that tumor microenvironment (TME) is closely associated with cancer prognosis. However, the prognostic signature for CCA based on TME has not yet been reported. This study aimed to develop a TME-related prognostic signature for accurately predicting the prognosis of patients with CCA. Methods: Based on the TCGA database, we calculated the stromal and immune scores using the ESTIMATE algorithm to assess TME in stromal and immune cells derived from CCA. TME-related differentially expressed genes were identified, followed by functional enrichment analysis and PPI network analysis. Univariate Cox regression analysis, Lasso Cox regression model and multivariable Cox regression analysis were performed to identify and construct the TME-related prognostic gene signature. Gene Set Enrichment Analyses (GSEA) was performed to further investigate the potential molecular mechanisms. The correlations between the risk scores and tumor infiltration immune cells were analyzed using Tumor Immune Estimation Resource (TIMER) database. Results: A total of 784 TME-related differentially expressed genes (DEGs) were identified, which were mainly enriched in immune-related processes and pathways. Among these TME-related DEGs, A novel two‑gene signature (including GAD1 and KLRB1) was constructed for CCA prognosis prediction. The AUC of the prognostic model for predicting the survival of patients at 1-, 2-, and 3- years was 0.811, 0.772, and 0.844, respectively. Cox regression analysis showed that the two‑gene signature was an independent prognostic factor. Based on the risk scores of the prognostic model, CCA patients were divided into high- and low-risk groups, and patients with high-risk score had shorter survival time than those with low-risk score. Furthermore, we found that the risk scores were negatively correlated with TME-scores and the number of several tumor infiltration immune cells, including B cells and CD4+ T cells. Conclusion: Our study established a novel TME-related gene signature to predict the prognosis of patients with CCA. This might provide a new understanding of the potential relationship between TME and CCA prognosis, and serve as a prognosis stratification tool for guiding personalized treatment of CCA patients.

Download Full-text

5-Methylcytosine RNA Methyltransferases-Related Long Non-coding RNA to Develop and Validate Biochemical Recurrence Signature in Prostate Cancer

Frontiers in Molecular Biosciences ◽

10.3389/fmolb.2021.775304 ◽

2021 ◽

Vol 8 ◽

Author(s):

Ke Wang ◽

Weibo Zhong ◽

Zining Long ◽

Yufei Guo ◽

Chuanfan Zhong ◽

...

Keyword(s):

Prostate Cancer ◽

Regression Analysis ◽

Biochemical Recurrence ◽

Prognostic Model ◽

Cox Regression ◽

Functional Enrichment ◽

Lasso Regression ◽

Clinical Value ◽

Cox Regression Analysis

The effects of 5-methylcytosine in RNA (m5C) in various human cancers have been increasingly studied recently; however, the m5C regulator signature in prostate cancer (PCa) has not been well established yet. In this study, we identified and characterized a series of m5C-related long non-coding RNAs (lncRNAs) in PCa. Univariate Cox regression analysis and least absolute shrinkage and selector operation (LASSO) regression analysis were implemented to construct a m5C-related lncRNA prognostic signature. Consequently, a prognostic m5C-lnc model was established, including 17 lncRNAs: MAFG-AS1, AC012510.1, AC012065.3, AL117332.1, AC132192.2, AP001160.2, AC129510.1, AC084018.2, UBXN10-AS1, AC138956.2, ZNF32-AS2, AC017100.1, AC004943.2, SP2-AS1, Z93930.2, AP001486.2, and LINC01135. The high m5C-lnc score calculated by the model significantly relates to poor biochemical recurrence (BCR)-free survival (p < 0.0001). Receiver operating characteristic (ROC) curves and a decision curve analysis (DCA) further validated the accuracy of the prognostic model. Subsequently, a predictive nomogram combining the prognostic model with clinical features was created, and it exhibited promising predictive efficacy for BCR risk stratification. Next, the competing endogenous RNA (ceRNA) network and lncRNA–protein interaction network were established to explore the potential functions of these 17 lncRNAs mechanically. In addition, functional enrichment analysis revealed that these lncRNAs are involved in many cellular metabolic pathways. Lastly, MAFG-AS1 was selected for experimental validation; it was upregulated in PCa and probably promoted PCa proliferation and invasion in vitro. These results offer some insights into the m5C's effects on PCa and reveal a predictive model with the potential clinical value to improve the prognosis of patients with PCa.

Download Full-text

Development and Validation of a 23-Gene Signature for Prognosis Prediction in Lung Adenocarcinoma

10.21203/rs.3.rs-272282/v1 ◽

2021 ◽

Author(s):

Jichang Liu ◽

Yadong Wang ◽

Weiqing Zhong ◽

Yong Liu ◽

Kai Wang ◽

...

Keyword(s):

Regression Analysis ◽

Lung Adenocarcinoma ◽

Protein Interactions ◽

Cox Regression ◽

External Validation ◽

Predictive Performance ◽

Gene Signature ◽

Lasso Regression ◽

Cox Regression Analysis ◽

Prognosis Prediction

Abstract Background: Lung cancer remains the most fatal tumorous disease in the worldwide. Among that, lung adenocarcinoma (LUAD) was the most common histological type. A precise and concise prognostic model was urgently needed of LUAD. We developed a 23-gene signature for prognosis prediction based on EMT, immune and stromal datasets.Methods: Univariate Cox regression analysis was performed to select genes which were significantly associated with overall survival (OS) of the TCGA LUAD cohorts. LASSO regression and multivariate Cox regression analysis was used to build the multi-gene signature. Enrichment analyses and a protein-protein interactions (PPI) network were performed to show the interaction and functions of the signature. A nomogram was developed based on risk score and other clinical features. Predictive performance of the signature was externally validated in two independent datasets from Gene Expression Omnibus (GSE37745 and GSE13213).Results: A total of 1334 EMT, immune and stromal associated genes were obtained. After LASSO regression and multivariate Cox regression analysis, a 23-gene signature for risk stratification was built. K-M curves showed that the patients with high risk had a poorer outcome. Finally, a nomogram was built to predict prognosis. The predictive performance of the 23-gene signature was confirmed in internal and external validation.Conclusion: We developed and verified a 23-gene signature based on EMT, immune and stromal gene sets. It provided a convenient and concise tool for risk stratificationand individual medicine.

Download Full-text

N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer

Recent Patents on Anti-Cancer Drug Discovery ◽

10.2174/1574892816666210615164645 ◽

2021 ◽

Vol 16 ◽

Author(s):

Jiao Jiao ◽

Longyang Jiang ◽

Yang Luo

Keyword(s):

Ovarian Cancer ◽

Regression Analysis ◽

Cox Regression ◽

Prognostic Indicator ◽

Gene Signature ◽

Genetic Alterations ◽

Lasso Regression ◽

Cox Regression Analysis ◽

Rna Methylation ◽

M6a Rna Methylation

Background: N6-Methyladenosine (m6A) RNA methylation is the most universal mRNA modification in eukaryotic cells. M6A mRNA modification affects almost every phases of RNA processing, including splicing, decay, export, translation and expression. Several patents have reported the application of m6A mRNA modification in cancer diagnosis and treatment. Ovarian cancer is the leading cause of death among all gynecological cancers. It is urgent to identify new biomarkers for early diagnosis and prognosis of ovarian cancer. Objective: In the current study, we aimed to evaluate the m6A RNA methylation regulators and m6A related genes and establish a new gene signature panel for prognosis of ovarian cancer. Method: We downloaded the Mutations data, FPKM data and corresponding clinical information of 373 patients with ovarian cancer (OC) from the TCGA database. We performed LASSO regression analysis and multivariate cox regression analysis to develop a risk-identifying gene signature panel. Results: A total of 317 candidate m6A RNA methylation related genes were obtained. Finally, 12 -genes (WTAP, LGR6, ZC2HC1A, SLC4A8, AP2A1, NRAS, CUX1, HDAC1, CD79A, ACE2, FLG2 and LRFN1) were selected to establish the signature panel. We analyzed the genetic alterations of the selected 12 -genes in OC using cBioPortal database. Among the 373 patients, 368 patients have mutations. The results showed that all queried genes were altered in 137 of 368 cases (37.23%). The 12-gene signature panel was confirmed as an independent prognostic indicator (P =2.29E-18, HR = 1.699, 95% CI = 1.508-1.913). Conclusion: We established an effective m6A-related gene signature panel consisted of 12 -genes, which can predict the outcome of patients with OC. The high risk score indicates unfavorable survival. Our study provided novel insights into the relationship between m6A and OC. This gene signature panel will be helpful in identifying poor prognostic patients with OC and could be a promising prognostic indicator in clinical practice.

Download Full-text

A Five-Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients

BioMed Research International ◽

10.1155/2020/4037639 ◽

2020 ◽

Vol 2020 ◽

pp. 1-13

Author(s):

Zeyu Wang ◽

Ningning Zhang ◽

Jiayu Lv ◽

Cuihua Ma ◽

Jie Gu ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Regression Analysis ◽

Cox Regression ◽

Early Stage ◽

Gene Signature ◽

Functional Enrichment ◽

High Recurrence Rate ◽

Lasso Regression ◽

Cox Regression Analysis ◽

Recurrence Prediction

Background. Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies with poor prognosis. There are many selectable treatments with good prognosis in Barcelona Clinic Liver Cancer- (BCLC-) 0, A, and B HCC patients, but the most crucial factor affecting survival is the high recurrence rate after treatments. Therefore, it is of great significance to predict the recurrence of BCLC-0, BCLC-A, and BCLC-B HCC patients. Aim. To develop a gene signature to enhance the prediction of recurrence among HCC patients. Materials and Methods. The RNA expression data and clinical data of HCC patients were obtained from the Gene Expression Omnibus (GEO) database. Univariate Cox regression analysis and least absolute shrinkage and selection operator (LASSO) regression analysis were conducted to screen primarily prognostic biomarkers in GSE14520. Multivariate Cox regression analysis was introduced to verify the prognostic role of these genes. Ultimately, 5 genes were demonstrated to be related with the recurrence of HCC patients and a gene signature was established. GSE76427 was adopted to further verify the accuracy of gene signature. Subsequently, a nomogram based on gene signature was performed to predict recurrence. Gene functional enrichment analysis was conducted to investigate the potential biological processes and pathways. Results. We identified a five-gene signature which performs a powerful predictive ability in HCC patients. In the training set of GSE14520, area under the curve (AUC) for the five-gene predictive signature of 1, 2, and 3 years were 0.813, 0.786, and 0.766. Then, the relative operating characteristic (ROC) curves of five-gene predictive signature were verified in the GSE14520 validation set, the whole GSE14520, and GSE76427, showed good performance. A nomogram comprising the five-gene signature was built so as to show a good accuracy for predicting recurrence-free survival of HCC patients. Conclusion. The novel five-gene signature showed potential feasibility of recurrence prediction for early-stage HCC.

Download Full-text

Identification of an immune gene signature with prognostic value for patients with uterine corpus endometrial carcinoma

10.21203/rs.3.rs-16901/v1 ◽

2020 ◽

Author(s):

Cankun Zhou ◽

Chaomei Li ◽

Fangli Yan ◽

Yuhua Zheng

Keyword(s):

Regression Analysis ◽

Endometrial Carcinoma ◽

Prognostic Value ◽

Prognostic Model ◽

Immune Cell ◽

Cox Regression ◽

Gene Signature ◽

Immune Gene ◽

Cox Regression Analysis ◽

Immune Genes

Abstract Background: Uterine corpus endometrial carcinoma (UCEC) is a very common gynecological malignancy with a poor prognosis in the late stage. Therefore, the purpose of this study was to determine an immune-related gene signature that predicts the patients’ OS for UCEC. Methods: Based on TCGA, ImmPort, and Cistrome databases, the differential immune genes were screened and the TFs regulatory network was constructed. Functional enrichment and pathway analysis of differential immune genes were carried out. Prognostic value of 410 immune genes was analyzed by Cox regression analysis, a prognostic model was constructed, ROC curves were used to verify the accuracy of the model, and independent prognostic analysis was performed. Finally, the immune cell content was obtained by TIMER, and the correlation with the immune gene expression was evaluated by univariate Cox regression analysis. Results: It was found that the immune cell microenvironment and PI3K-Akt, MARK signaling pathways were involved in the development of UCEC. Based on the established prognostic model, ten-gene prognosis signature (PDIA3, LTA, PSMC4, TNF, SBDS, HDGF, HTR3E, NR3C1, PGR, CBLC) for UCEC prognostic prediction were finally identified, and our study has shown that risk-score can be a powerful prognostic factor for UCEC, independent of other clinical factors. The levels of B cells and neutrophils may be significantly correlated with the patient's risk score. Conclusions: Our studies showed that the ten-gene prognosis signature had important clinical value for the prognosis of UCEC, which was helpful for individualized treatment and provided a new target for tumor immunotherapy.

Download Full-text

Prognosis Implication of a Novel Metabolism-Related Gene Signature in Ewing Sarcoma

Journal of Oncology ◽

10.1155/2021/3578949 ◽

2021 ◽

Vol 2021 ◽

pp. 1-14

Author(s):

Zhuo-Yuan Chen ◽

Huiqin Yang ◽

Jie Bu ◽

Qiong Chen ◽

Zhen Yang ◽

...

Keyword(s):

Regression Analysis ◽

Ewing Sarcoma ◽

Cox Regression ◽

Roc Curves ◽

Gene Signature ◽

Gene Expression Omnibus ◽

Prognostic Indicators ◽

Immune Checkpoints ◽

Lasso Regression ◽

Cox Regression Analysis

Ewing sarcoma (ES) is one of the most common bone cancers in adolescents and children. Growing evidence supports the view that metabolism pathways play critical roles in numerous cancers (He et al. (2020)). However, the correlation between metabolism-associated genes (MTGs) and Ewing sarcoma has not been investigated systematically. Here, based on the univariate Cox regression analysis, we get survival genes from differentially expressed genes (DEGs) from Gene Expression Omnibus (GEO) cohort. Multivariate Cox regression analysis and least absolute shrinkage and selection operator (LASSO) regression analysis were employed to establish the MTG signature. Comprehensive survival analyses including receiver operating characteristic (ROC) curves and Kaplan–Meier analysis were applied to estimate the independent prognostic value of the signature. The ICGC cohort served as the validation cohort. A nomogram was constructed based on the risk score of the MTG signature and other independent clinical variables. The CIBERSORT algorithm was applied to estimate immune infiltration. In addition, we explored the correlation between MTG signature and immune checkpoints. Collectively, this work presents a novel MTG signature for prognostic prediction of Ewing sarcoma. It also suggests six genes that are potential prognostic indicators and therapeutic targets for ES.

Download Full-text

Construction and Analysis of a Prognostic Model of Osteosarcoma Based on m6A-Related lncRNA

10.21203/rs.3.rs-966782/v1 ◽

2021 ◽

Author(s):

Zhian Ling ◽

Yuting Liang ◽

Suping Wei ◽

Yuanming Chen ◽

Jinmin Zhao

Keyword(s):

Regression Analysis ◽

Prognostic Model ◽

Cox Regression ◽

Risk Group ◽

Enrichment Analysis ◽

High Risk Group ◽

Gene Set Enrichment Analysis ◽

Lasso Regression ◽

Gene Set Enrichment ◽

Cox Regression Analysis

Abstract Background N6-methylandenosine (m6A) methylation is one of the most common methylation modifications in RNA. At present, a large number of studies have found that m6A methylation can regulate the occurrence and development of tumors by modifying mRNA. However, it is still unclear how m6A modifies Long non-coding RNA (lncRNA) that regulates mRNA expression by interacting with miRNA to affect the occurrence and development of osteosarcoma(OS). Therefore, exploring the lncRNAs related to m6A methylation and identifying lncRNAs that have both prognostic effects and immune functions are things that need to be solved urgently. Methods The published gene expression data of OS and complete clinical annotation files were obtained from the TARGET database. LncRNAs with P <0.001 from the results of Pearson correlation coefficient analysis as m6A-related lncRNAs were screened. Single-factor Cox regression analysis was used to screening prognostic- related lncRNA combined with the clinical information of patients and constructed a prognostic model based on lasso regression analysis. Then we explored the differences in survival and immune function of different subtypes that be obtained using the Consensus Cluster. The enrichment of differential genes between high and low risk groups in the KEGG pathway is achieved through Gene set enrichment analysis(GSEA). Results We obtained 706 lncRNAs in the TARGET database. Consensus clustering method were used to divide patients with OS into subgroups based on the expression of 26 prognostic-related lncRNAs. Through Kaplan-Meier survival analysis, there are significant differences between the two subgroups. The average immune score (P = 0.02), stromal score(P =0.027), and estimate score༈P = 0.015༉were higher in cluster 1 than in cluster 2. We found that compared with cluster 2, SIGLEC15, HAVCR2, LAG3, and PDCD1 were highly expressed in cluster 1.We obtain a prognostic model by lasso regression analysis. In the training group and the text group, the OS curve showed that patients in the high-risk group had a poorer prognosis than those in the low-risk group. In the training set, univariate Cox regression analysis and multivariate Cox regression analysis showed that the risk score was correlated with the prognosis of OS patients. In the high-risk group, the Linoleic acid metabolism and the Glycine, serine and threonine metabolism pathway were mainly involved by Gene Set Enrichment analysis. The abundance of Mast cells activated (P ≦0.024) and T cells CD4 (P ≦0.0044) naive were positively association the risk score. Conclusions This study clarified the important role of m6A-related lncRNAs in the prognosis and immune microenvironment of patients with OS, and indicate that m6A-related prognostic lncRNA signals may provide new targets for the diagnosis and treatment of OS.

Download Full-text

Identification of IGF2BP2 as a Prognostic Biomarker and Immunotherapeutic Target Based on Alternative Splicing Events in Glioblastoma

10.21203/rs.3.rs-900457/v1 ◽

2021 ◽

Author(s):

Xin-Yu Li ◽

Lei Hou ◽

Lu-yu Zhang ◽

Xue-yuan Li ◽

xi-tao Yang

Keyword(s):

Regression Analysis ◽

High Risk ◽

Prognostic Model ◽

Prognostic Markers ◽

Risk Model ◽

Cox Regression ◽

Prognostic Biomarker ◽

Low Risk ◽

Lasso Regression ◽

Cox Regression Analysis

Abstract Aim: A glioblastoma (GBM) prognostic model was developed with GBM -related alternative splicing (AS) data and prognostic markers were identified. Methods: AS data and clinical data of GBM patients were retrieved from The Cancer Genome Atlas (TCGA) SpliceSeq database and TCGA database, respectively. The data from these two databases were intersected to screen the prognosis-associated AS events, which was subsequently examined in Univariate Cox regression models. To avoid model overfitting, LASSO regression analysis was conducted. On the basis of these AS events, we established a prognostic model of GBM with the use of multivariate Cox regression analysis. On the strength of this model, the patients were assigned into high-risk and low-risk groups with a median risk score as the threshold. Kaplan-Meier survival, receiver operating characteristic (ROC), and calibration curves were applied to evaluate the performance of this model. Finally, combined with the risk model and clinicopathological characteristics, Cox regression analysis was utilized to identify the independent prognostic markers of GBM, and a nomogram was constructed. Results: The AS and clinical data of 169 GBM patients from the TCGA SpliceSeq and TCGA databases were collected. Univariate Cox regression analysis identified 1000 prognosis-related AS events in GBM, and then Lasso regression analysis identified 16 AS events. A GBM prognostic risk model was constructed based on AS events of 7 genes (FAM86B1, ZNF302, C19orf57, RPL39L, CBLL1, RWDD1, IGF2BP2). Through this model, we found lower overall survival (OS) rates of the high-risk population versus the low-risk population (p < 0.05). ROC and calibration curve analyses demonstrated the good ability of this model to predict the OS of GBM patients. Cox regression analysis suggested risk score as an independent prognostic factor for GBM. We also found that IGF2BP2 is associated with patient prognosis and have a strong relationship with immunotherapy response. Conclusion: The prognostic model based on AS events can significantly distinguish the survival rate of high-risk and low-risk GBM patients and IGF2BP2 were identified as a novel prognostic biomarker and immunotherapeutic target.

Download Full-text